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Abstract
BACKGROUND: There is a need to identify new markers to assess recurrence risk in early-stage colorectal cancer
(CRC) patients. We explored the prognostic impact of ether-a-gò-gò-related gene 1 channels and some hypoxia
markers, in patients with nonmetastatic (stage I, II, and III) CRC. METHODS: The expression of hERG1, vascular
endothelial growth factor A (VEGF-A), glucose transporter 1, carbonic anhydrase IX (CA-IX), epidermal growth factor
receptor (EGF-R), and p53 was tested by immunohistochemistry in 135 patients. The median follow-up was
35 months. Clinicopathologic parameters and overall survival were evaluated. RESULTS: hERG1 displayed a statis-
tically significant association with Glut-1, VEGF-A, CA-IX, and EGF-R; p53 with VEGF-A and CA-IX; Glut-1 with the age
of the patients; and EGF-R with TNM and mucin content. TNM and CA-IX were prognostic factors at the univariate
analysis; TNM, hERG1, and Glut-1, at the multivariate analysis. Risk scores calculated from the final multivariate
model allowed to stratify patients into four different risk groups: A) stage I-II, Glut-1 positivity, any hERG1; B) stage
I-II, Glut-1 and hERG1 negativity; C) stage I-II, Glut-1 negativity, hERG1 positivity; D) stage III, any Glut-1 and any
hERG1. CONCLUSIONS: hERG1 positivity with Glut-1 negativity identifies a patient group with poor prognosis within
stage I-II CRC. The possibility that these patients might benefit from adjuvant therapy, independently from the TNM
stage, is discussed. IMPACT: More robust prognostic and predictive markers, supplementing standard clinical and
pathologic staging, are needed for node-negative patients.
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Introduction
Colorectal cancer (CRC) accounts for approximately 9.4% of total
worldwide cancer causes and is the fourth most common cancer in
men and the third in women [1]. Clinical and pathologic tumor stag-
ing, contributing to TNM classification, are nowadays the main pre-
dictor of prognosis and treatment in patients with CRC [2]. However,
considerable stage-independent outcome variability is observed,
which likely reflects molecular heterogeneity. In particular, stage II
(node-negative) represents a wide spectrum of disease, where a 5-year
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survival can range from 85% to 50% [2]. Accordingly, the efficacy of
adjuvant chemotherapy, although well established in node-positive
CRC, needs to be fully validated for TNM stage II cases [3]. Hence,
more robust prognostic and predictive markers, supplementing standard
clinical and pathologic staging, are needed for node-negative patients.
Microsatellite instability and p53 alterations are among the most
frequent tumor alterations associated with CRC oncogenesis [4,5]. A
defect in mismatch repair accounts for approximately 15% colon cancers,
whereas p53 alterations are found in half of all CRCs [6,7]. Indeed,
microsatellite instability and p53 have been proposed to influence
the clinical outcome of CRC, but their usefulness for clinical use is still
under debate [8,9].
Molecular candidates implicated in CRC progression and potentially
useful for prognostic purposes can be singled out from the hypoxia
pathway. Tumor hypoxia is a key element of tumor progression, driving
to a more aggressive phenotype and an increased propensity for metas-
tases, as well as mediating radioresistance and chemoresistance [10,11].
Hypoxia can trigger such diverse effects because it switches on the
expression of hypoxia-inducible factor 1 (HIF-1)–dependent genes,
whose protein products allow tumor cells to survive the harsh tumor
microenvironment [12]. HIF-1–dependent genes comprise those trig-
gering the angiogenesis process [13]. Besides its relevance in tumor pro-
gression, the overlap between hypoxia and angiogenesis pathways can
be exploited for prognostic and predicting purposes [14]. However, a
thorough study evaluating the prognostic potential of hypoxia (and
angiogenesis) markers in CRC is lacking so far.
For these reasons, we performed a pilot study aimed at exploring
the prognostic impact of endogenous markers of tumor hypoxia in
CRC. On the basis of what was indicated in the study of Goethals
et al. [14], we determined the expression of 1) the vascular endothelial
growth factor A (VEGF-A) [15], as an example of HIF-1–dependent
gene; 2) carbonic anhydrase IX (CA-IX) [16], as a hypoxia marker
involved in the pH homeostasis; 3) the glucose transporter 1 (Glut-1)
[17], as a HIF-1–dependent gene and hypoxia marker involved in the
control of the metabolic state of neoplastic cells; and 4) the epidermal
growth factor receptor (EGF-R) [14,18], which triggers the intracellular
signaling pathways regulating HIF-1 activity in solid tumors [19]. In this
study, we also included the evaluation of the ether-a-gò-gò related gene
(hERG1) potassium channel, which is expressed in CRC [20–22] and
is functionally linked to hypoxia [23] and angiogenesis [24,25] in dif-
ferent types of cancer. The whole set of markers (VEGF-A, GLUT-1,
CA-IX, EGF-R, and hERG1) were tested by immunohistochemistry
(IHC) in surgical samples of nonmetastatic, TNM stages I to III,
CRC patients. A classic biomolecular marker, p53, and clinicopathologic
features were also included in the study. Overall survival (OS) was taken
as the main prognostic indicator.
Materials and Methods
Patients
The study cohort included 135 untreated patients who underwent
radical surgery with curative intent for colorectal adenocarcinomas at
the Department of General Surgery and Surgical Oncology, Azienda
Ospedaliero-Universitaria, Careggi, Florence. This cohort represents a
subgroup of the patients operated on at the Department in the period
September 2001 to July 2008 who were selected without any bias.
Patients affected by hepatitis C viral infection or who had undergone
preoperative radiotherapy or chemotherapy for rectal cancer were
excluded. Samples of tumor were collected during surgery, after ob-
taining an informed written consent, and immediately processed for
the sample storing (see next paragraphs). All the samples were classi-
fied as adenocarcinomas and staged according to the American Joint
Committee on Cancer classification by experienced pathologists.
Only samples that resulted to be TNM stages I to III were included in
the study and further processed for IHC. Patients with stage III received
adjuvant chemotherapy after surgery. All patients received the appro-
priate treatment after recurrence, according to the local guidelines.
Immunohistochemical Staining
IHC was carried out on 7-μm sections on positively charged slides.
After dewaxing and dehydrating the sections, endogenous peroxidases
were blocked with a 1% H2O2 solution in phosphate-buffered saline.
Subsequently, antigen retrieval was performed 1) by treatment with
proteinase K (5 μg/ml) (for hERG1, VEGF-A, CA-IX, and Glut-1
staining) or 2) by heating the samples in a microwave oven at 600 W
in citrate buffer pH 6.0 for 10 (for EGF-R staining) or 20 minutes (for
p53 staining). The following antibodies were used at the dilutions
reported in parentheses: 1) anti-hERG1 monoclonal antibody (1:200;
produced in our laboratory and distributed by Enzo Life Sciences,
Lawsen, Switzerland); 2) anti–VEGF-A (1:100, polyclonal antibody
anti–VEGF-A (A-20); Santa Cruz Biotechnology, Santa Cruz, CA); 3)
anti–Glut-1 (1:100, polyclonal rabbit anti–human GLUT1; Dako Cyto-
mation, Glostrup, Denmark); 4) anti–CA-IX monoclonal antibody
(monoclonal murine antibody M75, 1:100; described in Pastorekova
et al. [26]); 5) anti–EGF-R rabbit polyclonal IgG (1:100; Santa Cruz
Biotechnology); and 6) anti-p53 monoclonal antibody (1:50; Dako
Cytomation). Incubation with the primary antibody was carried out
overnight at 4°C, except for the anti-p53 antibody, which was incu-
bated for 30 minutes at room temperature. Immunostaining was per-
formed with a commercially available kit (PicTure Plus kit and DAB;
Zymed, Carlsbad, CA) according to the manufacturer’s instructions.
Specimens were evaluated using a quantitative assessment, using
different scoring systems based on the determination of the percent-
age of positive cells. Among the scoring systems used, different cutoffs
and a different number of groups were applied, the latter depending
on the staining pattern and intensity of the marker under study. We
adopted previously published scoring systems for VEGF-A, Glut-1,
CA-IX, EGF-R, and p53. In particular, the assignment of a positive
score was performed as follows: 1) For VEGF-A, when the sample
showed more than 10% positive cells [27]. 2) For Glut-1, when areas
displaying an unequivocal staining were detected, without using any
scoring system. Red blood cells served as an internal positive control,
whereas areas with normal epithelium, stroma, and edge effects were
ignored as in Cooper et al. [28]. 3) For CA-IX, as reported in Korkeila
et al. [29], without using a scoring system, samples were assessed as
positive when more than 10% cells per microscopic field expressed the
protein. 4) For EGF-R, when at least 1% positive cells were present in
the sample [30]. 5) For p53, a 10% cutoff was adopted, as reported in
Veloso et al. [31]. In any case, areas of necrosis, stroma, normal epithe-
lium, and distinct edge effects were not scored. To assess hERG1
expression, we first performed IHC experiments following the same
protocol published in Lastraioli et al. [20], using a polyclonal antibody
raised in our laboratory. To further validate this procedure, we per-
formed the same IHC using a monoclonal antibody recognizing a dif-
ferent epitope positioned in the S5 pore region of the channel [32].
Figure 1 shows representative sections stained with the anti-hERG1
polyclonal (A) and the anti-hERG1 monoclonal antibody (B). Both
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antibodies showed a clear and overlapping positivity in CRC cells, cor-
roborated by the good concordance emerged by the statistical analysis
carried out by χ2 test (P < .001). Because the monoclonal antibody gave
a very low background signal, which allowed us to better evaluate the
percentage of positive cells per microscopic field and therefore to assign
an immunoreactivity score to each sample, we decided to use this
antibody for further analyses. Stained sections were analyzed at a total
magnification of 40× field by field, from top left to bottom right. Each
field was assigned a percentage of positive tumor cells; hence, a semi-
quantitative scoring method was used and a cutoff of 50% was applied.
In other words, samples were classified as “score 0” when no staining
was present, “score 1” when displaying a positivity in a percentage rang-
ing from 1% to 49% of neoplastic cells, and “score 2” when the per-
centage of positive cells was more than 50%. Only samples displaying a
“score 2,” for example, with a strong hERG1 expression, were consid-
ered “positive” in further analyses. Figure 1 (C-E) shows representative
CRC sections displaying the different hERG1 scores.
In any case, samples were evaluated by two independent investiga-
tors. Interobserver agreement was evaluated according to the simple
Cohen κ of concordance and its 95% confidence interval (CI).
Statistical Analysis
The distributions of all studied patients were reported with respect to
their demographic, clinical, and biologic characteristics and were sum-
marized as frequencies and percentage. Continuous variables were re-
ported as median and range of variation. The following demographic
and clinical variables were investigated: age at the intervention, sex, site
of tumor, TNM classification, and presence of colloid. The biologic
assessment was evaluated through the expression of: hERG1 channels,
Glut-1, VEGF-A, CA-IX, p53, and EGF-R markers. All markers were
categorized as yes/no respect to their expression. Both in the association
and survival analysis, age was categorized in two groups (<70 years vs
≥70 years). The presence of association between demographic, clinical,
and biologic characteristics was evaluated by χ2 and Fisher exact tests
when appropriate. A two-sided P ≤ .05 was considered significant. All
the variables were investigated for their impact on OS. Because the
study was retrospective, and the patients were subjected to different
methods and timing of follow-up, we chose OS as the main end point.
OS was defined as the time between intervention and death, whatever
the cause. Observation time of patients alive at the last follow-up was
censored. Median follow-up time was estimated according to the Kaplan-
Meier inverse method [33]. In the univariate analysis, estimates of OS
were calculated according to the Kaplan-Meier product-limit method
[34]. Comparisons of estimated survival curves were performed by
means of the log-rank test. Hazard ratios and appropriate 95%CIs were
also calculated by means of the Cox proportional hazard model. A
multivariate Cox regression model was fitted to evaluate the indepen-
dent effect of each factor on OS. Starting from a full model, including
sex, age, site of tumor, TNM, colloid, hERG1, Glut-1, VEGF-A, and
CA-IX, nonsignificant variables were progressively removed according
to a backward stepwise procedure based on the likelihood ratio test. A
sensitivity analysis was also performed on 122 cases without missing
variables and including p53 and EGF-R information. A probability
of 0.10 was used both for removal and reentry criteria. Finally, we con-
verted the Cox model predictor to a risk score that is directly related to
an individual’s probability of death from any cause, and starting from
Figure 1. Scoring system assessment for hERG1 in CRC specimens. (A, B) Immunohistochemical detection of the hERG1 protein in the
same, representative specimen of CRC using two different anti-hERG1 antibodies: the anti-hERG1 polyclonal antibody (A) and the anti-
hERG1 monoclonal antibody (B). Bar, 100 μm. (C-E) Representative examples of hERG1 scoring (Materials and Methods) in CRC rep-
resentative specimens using the anti-hERG1 monoclonal antibody; details at higher magnification are in the insets: (C) score 0 (0% of
positive cells), (D) score 1 (1%-49% of positive cells per microscopic field), and (E) score 2 (>50% of positive cells per microscopic field).
Note that only samples belonging to score 2 were considered positive. Bar, 200 μm (C, D, E); 50 μm (insets).
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the distribution of risk scores and the strata identified by the combina-
tions of the three predictors retained in the Cox model, we empirically
classified all patients into four different risk groups.
Data were analyzed using the statistical software SAS 9.2 (SAS
Corporation, Cary, NC).
Results
Immunohistologic Findings
We studied 135 patients with stage I to III CRC, who underwent
radical surgery for primary CRC at a single institution. In all samples,
we determined the expression of hypoxia markers (VEGF-A, CA-IX,
Glut-1, and EGF-R), of hERG1 potassium channels, as well as of a
classic marker of CRC (p53) by IHC. IHC pictures relative to repre-
sentative samples of the all markers are in Figure 2. hERG1 (Figure 2A)
was expressed on the plasma membrane and in the cytoplasm of neo-
plastic cells, with a diffuse pattern of labeling and almost no staining in
the tumor stroma. VEGF-A (Figure 2B) staining was intense and dif-
fuse in the cytoplasm of tumor cells, with a weaker positivity in the
stroma, as reported [27]. Glut-1 (Figure 2C) stained the plasma mem-
brane and cytoplasm of tumor cells with a focal expression that might
be confined either to small or to slightly bigger areas or to bigger ones,
as reported [28]. CA-IX (Figure 2D) protein was expressed on the
plasma membrane of tumor cells, with a focal expression pattern, as
reported by Pastorekova et al. [26]. EGF-R (Figure 2E) staining was
mainly membranous, diffused to all tumor cells, although with different
intensities [30]. p53 (Figure 2F) stained tumor cell nuclei [31]. On the
basis of the scoring system chosen for each marker, a score value was
attributed to each sample. Note that only samples displaying a high
hERG1 staining (score 2, see Figure 1E) were considered positive for
further analyses. The κ value related to the interobserver measure of
agreement was 0.91 (95% CI = 0.84-0.98).
Clinical Characteristics
Table 1 shows the clinicopathologic characteristics of the patients,
as well as the distribution of the biologic markers under study. Of the
135 patients, 72 (53%) were female and 63 (47%) male. Median age was
68 years (range = 40-90 years). Fifty-seven tumors were located in the
right colon, 14 in the transverse, 33 in the left, and 31 in the rectum.
Relationship between Biologic Markers and
Clinical Characteristics
An IHC signal positive for hERG1 was observed in 23% of patients
(31/135). VEGF-A expression was detected in 82% (110/135), Glut-1
in 35% (47/135) of the samples, whereas CA-IX was expressed in 42 of
135 samples, accounting for 31%. EGF-R and p53 were positive in
78% (98/126) and 39% (51/131) of the samples, respectively (Table 1).
It emerged a statistically significant association between hERG1
and Glut-1 (P = .002), hERG1 and EGF-R (P = .050), hERG1 and
CA-IX (P = .018), hERG1 and VEGF-A (P = .049), VEGF-A and p53
(P = .002), and CA-IX and p53 (P = .030). A marginally statistically
significant association was observed between VEGF-A and CA-IX (P =
.070) and between VEGF-A and Glut-1 (P = .080). The percentage of
EGF receptor–expressing tumors significantly decreased according to
TNM stage (96%, 83%, and 64% for stage I, II, and III, respectively;
P for trend < .001) and in mucinous tumors (65% vs 83%, P = .032). A
marginally statistically significant association was also found between
Figure 2. Immunohistochemical staining for hERG1 (A), VEGF-A (B), Glut-1 (C), CA-IX (D), EGF-R (E), and p53 (F) in CRC specimens. IHC
experiments and assessment of score were performed according to what were reported in the Materials and Methods section. The
description of the staining features is in the Results section. Bar, 100 μm.
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Glut-1 and mucin, with Glut-1 less frequently expressed in mucinous
tumors (23% vs 39%, P = .080).
Impact on Survival
Median follow-up was 35 months. Overall, 55 (41%) of 135 patients
died during the period under investigation. At the univariate analysis,
whose results are reported in Table 1, the following variables turned out
to have a significant impact on OS: TNM stage and CA-IX expression.
Multivariate OS analysis, as reported in Table 2, identified the fol-
lowing independent prognostic factors: TNM, hERG1, and Glut-1.
In particular, as evident from the HR values, whereas TNM stage III
was confirmed to be an indicator of worse prognosis, hERG1 positivity
emerged as a negative prognostic factor. Conversely, Glut-1 positivity
had a positive impact of survival. The same results were confirmed by the
sensitivity analysis including p53 and EGF-R information (Materials
and Methods).
On the whole, from this analysis, it emerged that hERG1 positivity,
in conjunction with the lack of Glut-1 expression, has a negative prog-
nostic impact on survival that accompanies that of the TNM stage.
Starting from risk scores calculated from the final multivariate
model, patients were stratified into four different risk groups, three of
which comprised patients in TNM stages I and II, further subdivided
on the basis of the staining for hERG1 and Glut-1, and the fourth
group comprising stage III patients, as follows: A) TNM stage I-II, with
Glut-1 positivity, any hERG1; B) TNM stage I-II with Glut-1 nega-
tivity and hERG1 negativity; C) TNM stage I-II, with Glut-1 negativ-
ity and hERG1 positivity; and D) TNM stage III, any Glut-1 and any
hERG1. The relative percentage of stage I and stage II patients in the
A to C groups was roughly the same (see legend to Figure 3). As evident
from the Kaplan-Meier curves reported in Figure 3, the 3-year OS
probabilities in the four groups were as follows: 95%, 72%, 51%,
and 36%, respectively. It is worth noting that, in group C (i.e.,
TNM stages I and II, with Glut-1 negativity and hERG1 positivity)
and group D (TNM stage III, independent of hERG1 and Glut-1
staining), survival curves almost overlapped.
Discussion
To our knowledge, this study is the first that evaluates the impact of
different endogenous hypoxia markers, in conjunction with a K+ chan-
nel (hERG1), on OS of patients with nonmetastatic CRC. Our results,
although still preliminary and with all the limits of a retrospective study,
suggest for new clinical trials that the positivity for hERG1 and the neg-
ativity for Glut-1 allows to identify a patient’s group, within stage I and
II patients, which approaches the prognosis of stage III CRC.
The study evaluated the expression of Glut-1, CA-IX, VEGF-A,
EGF-R, along with hERG1 K+ channels by IHC in surgical samples
of nonmetastatic (TNM stages I to III) CRC patients, including a
classic biomolecular marker, p53, and clinicopathologic features, and
taking OS as the main prognostic indicator. The interobserver measure
of agreement was almost perfect.
We focused on the analysis of the hypoxia pathway because of the
relevance of this process and of the ensuing angiogenesis, in the ma-
lignant progression of cancer. Nevertheless, a thorough study assess-
ing the prognostic and predictive impact of hypoxia/angiogenesis
markers in CRC is lacking so far. Moreover, in our study, we also
evaluated the expression of hERG1 K+ channels. The inclusion was
dictated by the fact that K+ channels in general, and hERG1 in partic-
ular, are emerging as novel and believable biomarkers in several types
of cancers, including CRC [19,22] (http://www.sophicalliance.com/).
Moreover, our previous results indicated a functional link between
hERG1 and the hypoxia and angiogenesis pathways in different
cancer types [23–25] (Crociani et al., unpublished observations).
Indeed, a statistically significant association emerged between the
expression of hERG1 and that of all the other hypoxia markers ana-
lyzed. This result further confirms, in the clinical setting, what emerg-
ing from experimental data, and candidates, for the first time, a
potassium channel as a member of the endogenous hypoxia pathway,
at least in CRC. VEGF-A expression, besides strongly associated to
hERG1 expression, was also moderately associated with two other
markers of tumor hypoxia (CA-IX and Glut-1), as well as with the
presence of a mutated p53, witnessed by p53 IHC positivity. This
confirms that hypoxia, maybe through an increased HIF-1–mediated
Table 1. Distribution of Clinicopathologic and Biomolecular Markers and Results of the
Univariate Analysis.
Parameter No. Patients 3-Year Survival HR (95% CI) P (LR Test)
Age
<70 years 73 (54.1%) 0.59 1 (ref.) .652
≥70 years 62 (45.9%) 0.55 1.14 (0.65-1.97)
Sex
Female 72 (53.3%) 0.55 1 (ref.) .588
Male 63 (46.7%) 0.59 1.16 (0.67-2.02)
Tumor site
Right colon 57 (42.2%) 0.53 1 (ref.) .800
Left colon 33 (24.4%) 0.77 0.71 (0.34-1.51)
Transverse colon 14 (10.4%) 0.52 0.98 (0.40-2.44)
Rectum 31 (23.0%) 0.50 0.80 (0.40-1.59)
TNM stage
I 29 (21.5%) 0.74 1 (ref.) <.001
II 47 (34.8%) 0.74 0.83 (0.33-2.06)
III 59 (43.7%) 0.36 2.54 (1.17-5.52)
Mucin
No 100 (74.1%) 0.55 1 (ref.) .504
Yes 35 (25.9%) 0.60 0.81 (0.44-1.49)
hERG1
Negative 104 (77.0%) 0.59 1 (ref.) .203
Positive 31 (23.0%) 0.50 1.49 (0.80-2.76)
VEGF-A
Negative 25 (18.5%) 0.52 1 (ref.) .299
Positive 110 (81.5%) 0.58 0.69 (0.34-1.39)
Glut-1
Negative 88 (65.2%) 0.51 1 (ref.) .111
Positive 47 (34.8%) 0.68 0.60 (0.32-1.13)
CA-IX
Negative 93 (68.9%) 0.64 1 (ref.) .022
Positive 42 (31.1%) 0.31 2.02 (1.10-3.85)
EGF-R
Negative 28 (22.2%) 0.55 1 (ref.) .845
Positive 98 (77.8%) 0.58 0.94 (0.48-1.81)
p53
Negative 80 (61.1%) 0.55 1 (ref.) .876
Positive 51 (38.9%) 0.63 1.05 (0.58-1.88)
Table 2. Multivariate Analysis.
Variable Coefficient (SE) Hazard Ratio 95% CI P
TNM
I — 1 (Ref.) <.001
II −0.28611 (0.46752) 0.75 0.30-1.87
III 1.26618 (0.40922) 3.55 1.59-7.91
hERG1
Negative — 1 (Ref.)
Positive 0.76697 (0.33345) 2.15 1.12-4.13 .021
Glut-1
Negative — 1 (Ref.)
Positive −1.15571 (0.35403) 0.31 0.16-0.63 .001
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transcriptional activity of the vegf-a gene, selects p53-mutated, hypoxia-
resistant clones, thus contributing to CRC progression [8].
The univariate analysis of OS showed, in accordance with recent
analyses, that p53 IHC positivity had no significant impact on survival
of CRC patients, whereas it confirmed the prognostic role of the TNM
stage [2]. In addition, at the univariate analysis, CA-IX emerged as an
indicator of worse prognosis in CRC. The isozyme IX of carbonic
anhydrases contributes to control the tumor extracellular pH, while
Figure 3. Kaplan-Meier curves of overall survival according to different combinations of tumor characteristics (TNM stage, Glut-1 status,
and hERG1 status). Kaplan-Meier plots of overall survival probability for four different groups are reported. The number of patients in
each group is reported in parenthesis. Blue curve indicates Glut-1–positive samples (10 TNM I, 12 TNM II); red curve, Glut-1–negative
and hERG1-positive samples (5 TNM I, 5 TNM II); green curve, Glut-1–negative and hERG1-negative samples (14 TNM I, 30 TNM II);
black curve, TNM 3 patients (59 TNM III).
Figure 4.Model of the interplay between hERG1, Glut-1, and VEGF-A in CRC progression. When tumor mass (light pink circles) reaches
a critical volume, hypoxic areas start to be present, mainly in peripheral areas of the tumor (grey circles). In such condition, Glut-1 ex-
pression is triggered (gray triangle at the top). Subsequently, normoxic conditions are restored due to VEGF-A–mediated angiogenesis
(red circles inside the tumor mass and red rectangle at the top); VEGF-A secretion is regulated by hERG1 potassium channels, whose
expression is switched on (green triangle at the top). In this phase of tumor progression, Glut-1 expression is reduced (green triangle at
the top), tumor cells restart to grow and locally invade, reaching regional lymph nodes. In the latter stages of tumor progression, both
VEGF-A and hERG1 are overexpressed (red and blue rectangles at the top, respectively), intratumoral angiogenesis increases (red circles
in the tumor mass), and distant metastases occur.
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being strongly inducible by hypoxia in tumors [35,36]. This is also rel-
evant in CRC, where an increased CA-IX expression has been reported,
especially in the tumor areas of high proliferation [37]. Consistent with
our data, it was recently shown that CA-IX negativity is an independent
predictor of longer disease-free survival and OS in rectal cancers [29].
The multivariate analysis, while confirming the prognostic relevance
of the TNM stage, showed that only two of the markers we analyzed
remained in the Cox model: hERG1 and Glut-1. Interestingly, whereas
hERG1 positivity had a negative impact on OS, Glut-1, when positive,
was a predictor of good prognosis. In other words, the positivity of
hERG1 expression, in conjunction with the lack of Glut-1, reinforces
the well-established negative prognostic impact of the clinicopathologic
evaluation of the TNM stage.
It is possible to conceive a hypothetical model, which also takes into
account previously published results, where the interaction between
Glut-1 and hERG1 is interpreted (Figure 4). Glut-1 expression is high
as far as hypoxia is present within the tumor mass, whereas it is con-
ceivable that its expression declines as soon as normoxic conditions are
reestablished [38], and tumor cells restart growing and migrate outside
the tumor mass, reaching regional lymph nodes. This can be conse-
quence of the neoangiogenesis triggered by VEGF-A, whose secretion
is regulated by hERG1 channels [24,25]. Hence, a condition is estab-
lished, along tumor progression, which is characterized by the presence
of hERG1 and the progressive disappearance of Glut-1. Such condition
could allow the establishment of a more aggressive phenotype because
hERG1 not only drives VEGF-A secretion and increases CRC cell
invasiveness, a fact that explains its high expression in metastases [20].
Finally, the results of the multivariate analysis have some relevant
clinical consequences. In fact, starting from risk scores calculated from
the final multivariate model, patients were stratified into four different
risk groups, three of which comprising stage I and II patients, further
subgrouped on the basis of hERG1 and Glut-1 expression, and one
group that comprises all the stage III patients (Figure 3, curves). The
3-year OS probabilities inside the groups allowed us to conclude that
the patient group that displays positivity to hERG1 and a concomitant
negativity to Glut-1, despite belonging to TNM stages I or II, has a risk
probability that overlaps that of TNM stage III patients. This analysis
was not biased by any evident disequilibrium between the groups,
especially between stage I and stage II patients in the first three risk
groups. Hence, this result gets statistical significance and acquires
clinical relevance.
On the whole, the markers we propose (hERG1 and Glut-1), despite
the small number of cases we analyzed and besides the use of a non-
randomized study group, might identify a subgroup of patients with
regional, TNM stage I and II CRC, with a predictable worse prognosis.
These results, to be further considered for clinical trials for stage II CRC
patients, could conceivably provide an indication for a more aggressive
adjuvant therapy in stage II, hERG1 positive and Glut-1 negative, pa-
tients group.
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